top of page
MedMira's G4 HIV (FDA approved) rapid test - an independent evaluation by the CDC
Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens...
MedMira
5. Jan. 20231 Min. Lesezeit
Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®
Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMira
3. Jan. 20234 Min. Lesezeit
Copy of MedMira Introduces VYRA TriDemic
Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRATMproduct...
MedMira
29. Dez. 20223 Min. Lesezeit
MedMira's Multiplo TP/HIV Rapid Test. One Test, More Answers.
A study completed by the Indian Red Cross Blood Society showed that MedMira's Multiplo TP/HIV Rapid Test is your immediate quality...
MedMira
29. Okt. 20222 Min. Lesezeit
Dr. Hermes Chan, CEO, Co-Founder and Co-Inventor receives Queen's Jubilee Platinum Medal
Rafah DiCostanzo, MLA for Clayton Park West acknowledges outstanding constituents and has proposed Dr. Hermes Chan, CEO, Co-Founder and...
MedMira
19. Okt. 20221 Min. Lesezeit
MedMira receives CE mark for its VYRA™ COVID-19 Antigen Test
Halifax, Nova Scotia, 14 October, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™...
MedMira
14. Okt. 20222 Min. Lesezeit
bottom of page